SEC Filing Summary: Hillstream BioPharma, Inc. (HILS)
Business Context and Reporting Period
This Form 8-K was filed on July 5, 2023, by Hillstream BioPharma, Inc., a Delaware corporation and emerging growth company. The filing reports material events occurring between July 5 and July 11, 2023, including a strategic research collaboration and executive leadership appointments.
Key Financial Metrics and Agreements
The filing does not contain standard financial statements (revenue, profit, cash flow, or debt). Instead, it details financial obligations arising from new agreements:
- ABSI Collaboration Agreement:
- Initial Payment: Issuance of common stock valued at $250,000 within 30 days of the effective date.
- Financing Milestone: A mid-six-figure payment triggered if the Company raises over $10 million in net proceeds.
- Development Milestones: Up to $8,250,000 in aggregate payments upon achievement of specific milestones.
- Annual Fees: Low five-digit amount for the first year post-second anniversary; mid five-digit amount thereafter.
- Royalties: Quarterly royalties on net sales ranging from low to mid single digits, with tiered reductions for higher sales volumes.
- Transfer Fees: Mid single-digit to low double-digit percentages of net proceeds if rights are transferred to a third party.
- Executive Compensation:
- CEO (Randy Milby): Base salary of $500,000 annually; target bonus of 60% of base salary.
- COO (Sireesh Appajosyula): Base salary of $400,000 annually; target bonus of 50% of base salary.
Material Changes and Corporate Actions
The filing reports two primary material changes:
- Strategic Partnership: Entry into a Research and Development Collaboration and License Agreement with Applied Biomedical Science Institute (ABSI). The agreement grants Hillstream an exclusive, royalty-bearing license to ABSI patents and know-how for products targeting ErbB2 (Her2) and ErbB3. The collaboration includes a committee to manage preclinical studies leading to Phase 1 trials.
- Executive Appointments and Agreements:
- Sireesh Appajosyula, a board director since July 2021, was appointed Chief Operating Officer (COO) effective July 6, 2023. He resigned from the nominating and corporate governance committee.
- Employment agreements were executed for both the new COO and the CEO (Randy Milby), establishing five-year terms with automatic renewal provisions and specific severance packages tied to termination scenarios (Cause, Good Reason, Death, Disability, or Change of Control).
Outlook, Risks, and Contingencies
Outlook and Management Commentary: The ABSI agreement is designed to identify and evaluate products for the treatment, diagnosis, or prevention of disease in humans and animals. Upon successful completion of the discovery timeline for a target, Hillstream will exclusively own the resulting products. The agreement allows for the replacement of failed targets with new ones subject to ABSI approval.
Risks and Contingencies:
- Termination Rights: The ABSI agreement may be terminated by either party for material breach or bankruptcy. ABSI may terminate upon a "Challenge Proceeding," and Hillstream may terminate with 90 days' notice. Termination generally results in the reversion of all rights to ABSI.
- Severance Obligations: Significant financial contingencies exist regarding executive severance. In the event of a Change of Control followed by termination without Cause or termination for Good Reason, executives are entitled to accelerated equity vesting and severance equal to two times the sum of base salary and target bonus over a 24-month period.
- Confidentiality: Certain portions of the ABSI agreement were omitted from the public filing as confidential.
Key Facts for Investor Verification
- Verify the current stock price to calculate the exact number of shares to be issued to ABSI for the $250,000 initial payment.
- Confirm the specific definitions of "Net Proceeds" and "Company Expenses" in the full ABSI agreement to understand the triggers for the mid-six-figure financing payment and transfer fees.
- Review the full text of the employment agreements (Exhibits 10.2 and 10.3) to assess the total potential liability for severance in a Change of Control scenario.
- Monitor the progress of the preclinical studies for the ErbB2 and ErbB3 targets to evaluate the likelihood of achieving the $8.25 million in milestone payments.
- Check for any subsequent filings regarding the "Challenge Proceeding" risk factor mentioned in the ABSI agreement.